Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer

Anti-Cancer Drugs

Volumn 25, Issue 4, 2014, Pages 472-477

  Francini, Edoardo ^a   Fiaschi, Anna Ida ^b   Petrioli, Roberto ^b   Francini, Filippo ^b   Bianco, Vincenzo ^a   Perrella, Armando ^b   Paganini, Giovanni ^b   Laera, Letizia ^b   Roviello, Giandomenico ^b  

^a POLICLINICO UMBERTO I   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Abiraterone acetate; Castrate resistant prostate cancer; Prostate specific antigen

Indexed keywords

ABIRATERONE ACETATE; CYTOCHROME P450 17; MINERALOCORTICOID; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; CANCER GROWTH; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FOLLOW UP; HEMATURIA; HUMAN; HYPERTENSION; HYPOKALEMIA; JAW OSTEONECROSIS; LIVER FUNCTION TEST; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROSTENOLS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MINERALOCORTICOIDS; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84896395869     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000072     Document Type: Article

References (27)

1. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10: 981-991.
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. (Pubitemid 39315317)
3. Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011; 8: 551-561.
4. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764. (Pubitemid 26185452)
5. Garmey EG, Sartor O, Halabi S, Vogelzang NJ. Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol 2008; 6: 118-127.
6. Petrioli R, Fiaschi AI, Francini E, Pascucci A, Francini G. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat Rev 2008; 34: 710-718.
7. Francini F, Pascucci A, Francini E, Bargagli G, Conca R, Licchetta A, et al. Bevacizumab and weekly docetaxel in patients with metastatic castrateresistant prostate cancer previously exposed to docetaxel. Prostate Cancer 2011; 2011:258689.
8. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
9. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
10. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
11. Bedoya DJ, Mitsiades N. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Expert Rev Anticancer Ther 2012; 12: 1-3.
12. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407-6415.
13. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-148.
14. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2009; 92: 205-261.
15. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
16. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1: 277-299.
17. De Benedittis G, Massei R, Nobili R, Pieri A. The Italian Pain Questionnaire. Pain 1988; 33: 53-62.
18. McCormack A, Hunter-Smith D, Piotrowski ZH, Grant M, Kubik S, Kessel K. Analgesic use in home hospice cancer patients. J Fam Pract 1992; 34: 160-164.
19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376. (Pubitemid 23073154)
20. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2006; 28: 1496-1501.
21. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, et al. Significant and sustained antitumor activity in post docetaxel, castrationresistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-1495.
22. Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 2010; 70: 1256-1264.
23. Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl Res 2009; 1: 148-162.
24. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castrationresistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2006; 17: 5913-5925.
25. Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther 2012; 6: 13-18.
26. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000; 6: 703-706. (Pubitemid 30398797)
27. Oudard S. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev 2013; 39: 275-289.